标题
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 3, Pages 1102
出版商
MDPI AG
发表日期
2020-02-08
DOI
10.3390/ijms21031102
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Editor's Note: p38 Mitogen-activated Protein Kinase Pathway Suppresses Cell Survival by Inducing Dephosphorylation of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase1,2
- (2020) Song-Ping Li et al. CANCER RESEARCH
- ONECUT2 is a driver of neuroendocrine prostate cancer
- (2019) Haiyang Guo et al. Nature Communications
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
- (2019) Ophélia Maertens et al. Cancer Discovery
- Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
- (2019) Romi Gupta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
- (2019) Michael F. Emmons et al. CANCER RESEARCH
- Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with vemurafenib.
- (2019) Govind Warrier et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
- (2019) Min-Wu Chao et al. Clinical Epigenetics
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
- (2019) Srinivas Patnaik et al. Frontiers in Pharmacology
- Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
- (2019) Daphné Morel et al. Nature Reviews Clinical Oncology
- Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
- (2019) Khaliq et al. Cancers
- Principles and mechanisms of non-genetic resistance in cancer
- (2019) Charles C. Bell et al. BRITISH JOURNAL OF CANCER
- USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer
- (2019) Robyn Laura Kosinsky et al. Cell Death & Disease
- ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression
- (2019) Qingyang Ma et al. Scientific Reports
- CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies
- (2019) William W. Feng et al. Cell Reports
- Targeting Epigenetics in Cancer
- (2018) Richard L. Bennett et al. Annual Review of Pharmacology and Toxicology
- Targeting FBPase is an emerging novel approach for cancer therapy
- (2018) Gao-Min Liu et al. Cancer Cell International
- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- (2018) Florian Rambow et al. CELL
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
- (2018) Liqin Wang et al. CELL
- MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
- (2018) Zheng Xue et al. CELL RESEARCH
- Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
- (2018) Rasmi R. Mishra et al. CLINICAL CANCER RESEARCH
- Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
- (2018) Mohd Wahid et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
- (2018) Ileabett M Echevarría‐Vargas et al. EMBO Molecular Medicine
- Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors
- (2018) Elnaz Faghfuri et al. Expert Opinion on Drug Metabolism & Toxicology
- Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma
- (2018) Shomereeta Roy et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours
- (2018) Javier Garcia-Bermudez et al. NATURE CELL BIOLOGY
- ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
- (2018) Andrew M. Kidger et al. PHARMACOLOGY & THERAPEUTICS
- Cancer epigenetics: Moving forward
- (2018) Angela Nebbioso et al. PLoS Genetics
- The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation
- (2018) Nomeda Girnius et al. eLife
- Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
- (2018) Oleksii S. Rukhlenko et al. Cell Systems
- Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
- (2018) Yiu To Yeung et al. EBioMedicine
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway
- (2018) Ping Yang et al. CANCER LETTERS
- Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
- (2018) Hiroki Sato et al. CANCER SCIENCE
- Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis
- (2018) Jacob Insua‐Rodríguez et al. EMBO Molecular Medicine
- Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells
- (2018) Xiaolu Han et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
- (2018) Sabrina Rizzolio et al. JOURNAL OF CLINICAL INVESTIGATION
- Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
- (2018) Francesca Zanconato et al. NATURE MEDICINE
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- (2018) Thomas Strub et al. Nature Communications
- AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel
- (2018) MASAHIRO YAMAMOTO et al. ANTICANCER RESEARCH
- ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
- (2018) Mirja Rotinen et al. NATURE MEDICINE
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
- (2018) Tonći Šuštić et al. Genome Medicine
- MEK inhibitors in oncology: a patent review (2015-Present)
- (2017) Debarshi Kar Mahapatra et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development
- (2017) Nivedita M. Ratnam et al. JOURNAL OF CLINICAL INVESTIGATION
- Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells
- (2017) Xiaomin Feng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
- (2017) Caner Saygin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
- (2017) Giulia Cesi et al. Molecular Cancer
- Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells
- (2017) Kayleigh C. Ross et al. MOLECULAR CANCER THERAPEUTICS
- Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation
- (2017) Ting Zhao et al. Molecular Medicine Reports
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
- (2017) Hezhe Lu et al. NATURE
- A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
- (2017) Gao Guo et al. NATURE NEUROSCIENCE
- Targeting the unfolded protein response in cancer
- (2017) Rani Ojha et al. PHARMACOLOGICAL RESEARCH
- Epigenetic plasticity and the hallmarks of cancer
- (2017) William A. Flavahan et al. SCIENCE
- Serine and Functional Metabolites in Cancer
- (2017) Alice C. Newman et al. TRENDS IN CELL BIOLOGY
- Distinct histone modifications denote early stress-induced drug tolerance in cancer
- (2017) Abdullah Al Emran et al. Oncotarget
- Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer
- (2017) Yonglei Liu et al. Oncotarget
- Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
- (2017) Keisha N. Hardeman et al. Scientific Reports
- Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway
- (2016) Kang Qi et al. ANTI-CANCER DRUGS
- Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin
- (2016) Yi-Te Lin et al. BIOCHEMICAL PHARMACOLOGY
- ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
- (2016) Taru Muranen et al. CANCER RESEARCH
- Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β
- (2016) Eva Martini et al. CELL CYCLE
- The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
- (2016) Yufang Ma et al. CLINICAL CANCER RESEARCH
- p38 MAP kinases in the heart
- (2016) Tomohiro Yokota et al. GENE
- JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships
- (2016) András Zeke et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
- (2016) R. Rincon et al. MOLECULAR CANCER THERAPEUTICS
- Tumour-specific proline vulnerability uncovered by differential ribosome codon reading
- (2016) Fabricio Loayza-Puch et al. NATURE
- Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
- (2016) Haiyang Guo et al. NATURE GENETICS
- Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
- (2016) Andrew P. Feinberg et al. NATURE REVIEWS GENETICS
- Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
- (2016) A N Paranjape et al. ONCOGENE
- Integrating network reconstruction with mechanistic modeling to predict cancer therapies
- (2016) M. Halasz et al. Science Signaling
- The Warburg Effect: How Does it Benefit Cancer Cells?
- (2016) Maria V. Liberti et al. TRENDS IN BIOCHEMICAL SCIENCES
- BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
- (2016) Ying-Ying Li et al. Oncotarget
- Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
- (2016) Samuel Gonçalves-Ribeiro et al. Oncotarget
- The molecular and clinical verification of therapeutic resistance via the p38 MAPK–Hsp27 axis in lung cancer
- (2016) Chia-Lin Liu et al. Oncotarget
- p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells
- (2016) Shin-Hyung Park et al. Oncotarget
- Integrating network reconstruction with mechanistic modeling to predict cancer therapies
- (2016) M. Halasz et al. Science Signaling
- BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
- (2016) Luca Paoluzzi et al. Cancer Medicine
- Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation
- (2015) Pablo G. Jambrina et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Natural course and biology of CML
- (2015) Bradley Chereda et al. ANNALS OF HEMATOLOGY
- PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
- (2015) Samuel W Brady et al. CANCER BIOLOGY & THERAPY
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- The Stress Kinase p38 as a Target for Cancer Therapy
- (2015) A. Igea et al. CANCER RESEARCH
- Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
- (2015) Francisco Azuaje et al. Cell Communication and Signaling
- HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
- (2015) R. Carson et al. CLINICAL CANCER RESEARCH
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- The Warburg effect: Evolving interpretations of an established concept
- (2015) Xiaozhuo Chen et al. FREE RADICAL BIOLOGY AND MEDICINE
- JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases
- (2015) Ankit Kumar et al. Future Medicinal Chemistry
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15
- (2015) HONG JI et al. Molecular Medicine Reports
- Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
- (2015) Franziska Baenke et al. Molecular Oncology
- Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
- (2015) M. Fallahi-Sichani et al. Molecular Systems Biology
- IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance
- (2015) XIAO-LEI YE et al. ONCOLOGY REPORTS
- Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel
- (2015) MANABU SEINO et al. ONCOLOGY REPORTS
- MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
- (2015) Pui-Kei Wu et al. SEMINARS IN ONCOLOGY
- IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
- (2015) Zhen Ning Wee et al. Nature Communications
- Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals
- (2015) Hongjun Xie et al. Oncotarget
- Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib
- (2015) Zhe Li et al. Thoracic Cancer
- Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects
- (2015) Boris N. Kholodenko Cell Reports
- PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer
- (2015) Yanjie Zhang et al. EBioMedicine
- Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
- (2015) Masashi Okada et al. Oncotarget
- Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition
- (2015) Qiong Wang et al. Oncotarget
- Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
- (2014) Thuy V. Nguyen et al. BIOMATERIALS
- Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
- (2014) R. Haq et al. CLINICAL CANCER RESEARCH
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- SAICAR Induces Protein Kinase Activity of PKM2 that Is Necessary for Sustained Proliferative Signaling of Cancer Cells
- (2014) Kirstie E. Keller et al. MOLECULAR CELL
- Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
- (2014) Jelena Urosevic et al. NATURE CELL BIOLOGY
- Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
- (2014) Guangyuan Li et al. PLoS One
- Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade
- (2014) X. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
- (2014) Valentina Grossi WORLD JOURNAL OF GASTROENTEROLOGY
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
- (2014) T. J. Parmenter et al. Cancer Discovery
- Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
- (2014) E. C. de Bruin et al. Cancer Discovery
- JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy
- (2014) Xinbing Sui et al. Scientific Reports
- JNK signalling in cancer: in need of new, smarter therapeutic targets
- (2013) Concetta Bubici et al. BRITISH JOURNAL OF PHARMACOLOGY
- PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
- (2013) Francisca Vazquez et al. CANCER CELL
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors
- (2013) K. J. Basile et al. CANCER RESEARCH
- RANK expression on breast cancer cells promotes skeletal metastasis
- (2013) Michelle L. Blake et al. CLINICAL & EXPERIMENTAL METASTASIS
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
- (2013) S.M. Donnelly et al. CURRENT MEDICINAL CHEMISTRY
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
- (2013) D Wetterskog et al. ONCOGENE
- Epigenetic Reprogramming in Cancer
- (2013) M. L. Suva et al. SCIENCE
- Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
- (2013) M R Milone et al. Cell Death & Disease
- Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation
- (2013) A Notte et al. Cell Death & Disease
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Roles of p38 MAPKs in invasion and metastasis
- (2012) Ivan del Barco Barrantes et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
- (2012) Jueng Soo You et al. CANCER CELL
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
- (2012) Patrick S. Ward et al. CANCER CELL
- HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway
- (2012) Y Yao et al. CANCER GENE THERAPY
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Quercetin Suppresses Drug-Resistant Spheres via the p38 MAPK–Hsp27 Apoptotic Pathway in Oral Cancer Cells
- (2012) Su-Feng Chen et al. PLoS One
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Computational Approaches for Analyzing Information Flow in Biological Networks
- (2012) B. Kholodenko et al. Science Signaling
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
- (2011) Davide Torti et al. EMBO Molecular Medicine
- The role of JNK in the development of hepatocellular carcinoma
- (2011) Madhumita Das et al. GENES & DEVELOPMENT
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
- (2011) M. Cargnello et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
- (2011) Craig J. Ceol et al. NATURE
- The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
- (2011) Daniel Schramek et al. NATURE GENETICS
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms and functions of p38 MAPK signalling
- (2010) Ana Cuadrado et al. BIOCHEMICAL JOURNAL
- Pathological roles of MAPK signaling pathways in human diseases
- (2010) Eun Kyung Kim et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer
- (2010) K. G. Finegan et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Mitochondrial Localization and Regulation of BRAFV600Ein Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E
- (2010) Min Hee Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib
- (2010) Disha Dumka et al. LEUKEMIA & LYMPHOMA
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
- (2010) O. E. Sturm et al. Science Signaling
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
- (2009) J. Yun et al. SCIENCE
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- c-Jun NH2-Terminal Kinase 1 Is a Critical Regulator for the Development of Gastric Cancer in Mice
- (2008) W. Shibata et al. CANCER RESEARCH
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- The complexity of mitogen-activated protein kinases (MAPKs) made simple
- (2008) M. Krishna et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
- (2008) Lijian Hui et al. JOURNAL OF CLINICAL INVESTIGATION
- An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
- (2008) R. Aesoy et al. MOLECULAR CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started